This kind of cancer over 60%of patients will be advanced in the first diagnosis!Xiehe released the latest breakthrough ...

The reporter learned from Xiehe Hospital Affiliated to the Tongji Medical College of Huazhong University of Science and Technology on July 12 that the global top -level journal "Clinical Cancer Research" published a research results of the hospital's head and neck tumor MDT team on June 29. This journal determines that this is the world's first clinical research data for newly-assisted chemotherapy combined with PD-1 antibody treatment for local advanced head and neck squamous carcinoma.

The authoritative journal "ClinicalCancerresearch" in the global cancer treatment field published the clinical research data.

The results of the research show that this newly -assisted chemotherapy combined immunotherapy model with the original innovation characteristics enables the treatment effective rate of local advanced throat cancer, nasal cancer, and oral cancer, far exceeding historical treatment plans. Professor Yang Kunyu, the head of the team and director of the Cancer Department of Xiehe Hospital, said that the combined immunotherapy model of the neoadermination not only significantly increased the tumor cure rate, but also allowed the patient Subcontaneous carcinoma patients provide a new treatment option.

At the press conference, Professor Yang Kunyu of the Cancer Center of Xiehe Hospital introduced the research situation.

Can get a more high cure rate free of "cut throat" pain

my country ’s head and neck squamous carcinoma is the ninth largest common cancer in my country. Due to the first diagnosis of patients and neck tumors with symptoms of more than 60%of the symptoms, more than half of the patients with tumor recurrence or metastasis will occur. The recommended treatment mode of international and domestic guidelines is test -of -treatment surgery tie radiotherapy, or radical chemotherapy during the same period. The 5 -year survival rate is about 40 %. "Throat", the throat will also leave a conspicuous presence, and it will be hit by physical and mental physical and mental.

In 2019, Professor Yang Kunyu and Professor Zhang Xiaomeng led the formation of the MDT team to explore the new type of treatment model. MDT is a multi -disciplinary diagnosis and treatment model, which is a modern diagnosis and treatment model widely regarded in the international medical field. The MDT team of the head and neck tumor is composed of an ear, throat, throat and neck surgery, dental department, oncology, imaging and pathology experts. The diagnosis and treatment plan of each patient will be discussed by the team members and formulated treatment decisions.

Professor Zhang Xiaomeng at the Department of ENT of Xiehe Hospital.

Patients who meet the research conditions will first receive a three -course new auxiliary chemotherapy combined with immunotherapy, and then undergo radical surgery. New -assisted chemotherapy combined with immunotherapy can rapidly reduce the volume of the tumor or even disappear, making it easier to be completely removed, and removes a small metastatic lesion in the patient's body. "Immunotherapy has established magical skills in this new treatment model." Professor Yang Kunyu said that cunning cancer cells can cause human immune T cells to lose their ability to identify and combat it. Immunotherapy uses a PD-1 antibody to restore the killing effect of immune cells on tumor cells and reverse the immune escape of tumor cells. And immunotherapy has a memory effect. Once valid, it can monitor tumor cells for a long time and remove tumor recurrence or metastatic lesions.

Studies have proved that this new treatment strategy can make the tumors of patients with local advanced head and neck squamous carcinoma significantly retract or even disappear, which can be completely removed, may obtain organ function retention, and higher healing opportunities. In the words of Professor Yang Kunyu: The new therapy not only "cuts clean" the tumor to avoid recurrence and transfer, but also allows patients to remove the suffering of "cutting throats and disappointment".

More than 50 cases of new therapy patients

"I eat well now, sleep well, and have a good condition." On July 12, Mr. Ma, a 62 -year -old Mr. Ma, reviewed his appearance. The 62 -year -old gentleman is like a cigarette and alcohol. In May 2020, he was clinic at Xiehe Hospital because of the "hoarseness of the pharyngeal foreign body and swallowing obstruction". Diagnosis is a local advanced pharynxial squamous carcinoma, clinical staging IVA stage.

"According to the traditional surgical method, Mr. Ma needs full throat resection, but he himself expressed that he could not accept it." Another MDT team leader, otolaryngus and throat head and neck surgery, Professor Zhang Xiaomeng, introduced that after three cycles of neo -auxiliary chemotherapy combined After immunotherapy, Mr. Ma's tumor lesions were significantly reduced. When the pharyngeal lesions were evaluated before surgery, no clear tumor lesions were seen, and tumor cells were not found in subsequent surgical specimens. In the end, the surgery was successfully removed, and the throat was kept at the same time. After the operation, Mr. Ma returned well and returned to normal life.

Patients like Mr. Ma have cured more than 50 examples.

The results of the research show that newly adjusted chemotherapy can further combine immunotherapy to achieve better curative effects. The tumor efficiency is 96%, while historical data is 60 ~ 70%; Pathology> 90%relief) 74%. These data far exceed the image and pathological relief rate of historical treatment solutions.

Professor Yang Kunyu introduced that the benefits of the new treatment model also include: reducing tumors before surgery, reducing surgery, reducing surgical complications; immunotherapy or having the start of the start of T cells and promoting the expansion of anti -tumor T cells, which can then be possible. Clear tiny cancer metastases.

According to reports, the MDT team of the Hohe Hospital's head and neck tumor has been established for 7 years, integrating many expert teams such as otolaryngomy, stomatology, tumor mortar chemotherapy, plastic surgery, pathology, video department, and nuclear medicine. In the future, the team will continue to be committed to the foundation and clinical study of the immunotherapy of scales and neck squamous cell carcinoma on the advanced and recurrence of the advanced and recurrent head and neck. While creating cure, it will improve the quality of life of patients.

37 degrees 丨 Yangtze Health Rong Media Product

Reporter: Roland

Correspondent: Zhang Wei Xiong Wanting Photography: Liu Kunwei

Edit: Gaoyang

For more exciting content, please download the "Da Wuhan" client in the major application markets.

- END -